ArcticZymes Technologies ASA (OSL:AZT)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.06B |
| Revenue (ttm) | 118.21M |
| Net Income (ttm) | 9.88M |
| Shares Out | 51.07M |
| EPS (ttm) | 0.19 |
| PE Ratio | 109.47 |
| Forward PE | 52.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,747 |
| Average Volume | 69,989 |
| Open | 20.00 |
| Previous Close | 19.95 |
| Day's Range | 19.95 - 21.40 |
| 52-Week Range | 14.50 - 31.40 |
| Beta | 0.52 |
| RSI | 54.66 |
| Earnings Date | Apr 30, 2026 |
About OSL:AZT
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other... [Read more]
Financial Performance
In 2025, OSL:AZT's revenue was 118.21 million, an increase of 9.34% compared to the previous year's 108.11 million. Earnings were 9.88 million, an increase of 16.66%.
Financial StatementsNews
ArcticZymes Technologies ASA Transcript: CMD 2026
The company is executing a strategy to scale its enzyme platform through diversification, innovation, and customer-centric solutions, targeting high-growth markets like metagenomics and RNA therapeutics. Strong financials, validated customer impact, and a focus on operational leverage underpin ambitions for double-digit growth and market outperformance.
ArcticZymes Technologies ASA Earnings Call Transcript: Q4 2025
Q4 and full year 2025 delivered strong revenue and EBITDA growth, driven by commercial transformation, product portfolio expansion, and strategic partnerships. Biomanufacturing and molecular tools segments both showed robust performance, with momentum expected to continue into 2026.
ArcticZymes Technologies ASA Earnings Call Transcript: Q3 2025
Q3 saw 24% revenue growth and a return to profitability, driven by strong molecular tools and biomanufacturing performance. A major European partnership and robust cash position set the stage for long-term growth, with new applications and markets fueling future expansion.
ArcticZymes Technologies ASA Earnings Call Transcript: Q2 2025
Q2 saw 5% revenue growth and a 50% EBITDA increase, driven by record biomanufacturing sales and the launch of M-SAN HQ GMP. Molecular tools faced a temporary dip but are set for recovery as key customers return. Strong cash reserves and strategic investments position the company for continued growth.
ArcticZymes Technologies ASA Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined due to a temporary drop from a major OEM customer, but biomanufacturing sales grew 21% year-over-year and the customer base reached record highs. Strategic investments in commercial transformation and new CDMO partnerships are driving future growth.
ArcticZymes Technologies ASA Earnings Call Transcript: Q4 2024
Q4 2024 saw revenue of NOK 24.4 million and EBITDA of NOK 2.7 million, with improved margins and a broader customer base despite a year-over-year decline. Strategic transformation, new product launches, and a strong cash position set the stage for growth in 2025.
ArcticZymes Technologies ASA Earnings Call Transcript: Q3 2024
Q3 saw a revenue decline to NOK 23.3 million and negative EBITDA, mainly due to weak Molecular Tools sales and challenging market conditions. Biomanufacturing showed growth, and strategic investments in commercial transformation and new product launches are expected to drive future performance.
ArcticZymes Technologies ASA Earnings Call Transcript: Q2 2024
Q2 2024 saw record order volume and steady progress in innovation, partnerships, and regulatory compliance, despite a slight revenue decline. New product launches and partnership deals are expected to drive future growth, with strong liquidity supporting ongoing investments.